{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-042919","form_type":"8-K","ticker":null,"cik":"0001733413","company_name":"TFF Pharmaceuticals, Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.801979+00:00","generated_at":"2026-06-02T01:05:42.650194+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TFF Pharma Q1 net loss $5.7M, cash $3.2M; raised $6M in public offerings since March","bullets":["Net loss of $5.7M improved from $7.1M in Q1 2023; R&D spend $3.6M, G&A $2.4M.","Cash and equivalents $3.2M at March 31; completed $4.8M offering May 1, plus $1.2M in March.","Phase 2 TFF TAC: 8/8 patients transitioned from oral; 4/4 completed 12 weeks and entered extension.","TFF VORI: 5/6 patients achieved clinical and mycologic response; no IPA-related mortality.","Company prioritizing TFF TAC; exploring strategic alternatives for TFF VORI; FDA feedback expected in Q2."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-042919","json":"https://secwatch.observer/filing/0001213900-24-042919.json","markdown":"https://secwatch.observer/filing/0001213900-24-042919.md","text":"https://secwatch.observer/filing/0001213900-24-042919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/0001213900-24-042919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/ea0206069-8k_tffpharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:05:42.650194+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f88d3b9c66c0c84f14d2533622292b8d2e0b9c74","claim":"TFF Pharmaceuticals, Inc. reported fiscal quarter ended March 31, 2024 results: net income Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.","evidence_excerpt":"Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.1 million for the year ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1733413/000121390024042919/0001213900-24-042919-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}